Moleculin Biotech
MBRX
18 hedge funds and large institutions have $2.91M invested in Moleculin Biotech in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 2 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
56% more capital inflows, than outflows
Capital inflows: $123K | Capital outflows: $78.8K
13% more funds holding
Funds holding: 16 → 18 (+2)
0.12% more ownership
Funds ownership: 10.45% → 10.57% (+0.12%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Squarepoint
New York
|
+$26.3K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$17.5K |
| 3 |
HRT Financial
New York
|
+$17.5K |
| 4 |
Renaissance Technologies
New York
|
+$17.5K |
| 5 |
Two Sigma Securities
New York
|
+$17.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Charles Schwab
San Francisco,
California
|
-$38.8K |
| 2 |
Sio Capital Management
New York
|
-$26.3K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$11.9K |
| 4 |
Rockefeller Capital Management
New York
|
-$1K |
| 5 |
Clearstead Advisors
Cleveland,
Ohio
|
-$636 |
MBRX Hedge Fund Activity: Q1 2023 in Review
18 of the 6,289 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q1 2023, worth a combined $2.91M — down 8.4% from $3.17M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new MBRX positions and 2 closed out — a net gain of 2 holders — while 4 added to existing stakes and 1 trimmed.
The largest buyer was Squarepoint, opening a new position worth an estimated $26.3K. The largest seller was Charles Schwab, exiting entirely with an estimated $38.8K sold.
- 18 institutional investors held Moleculin Biotech (MBRX) as of Q1 2023, up from 16 in Q4 2022.
- Funds reported $2.91M of Moleculin Biotech stock for Q1 2023, down 8.4% quarter-over-quarter.
- 4 funds opened new Moleculin Biotech positions in Q1 2023 and 2 closed out, a net change of +2 holders.
- The largest Moleculin Biotech buyer in Q1 2023 was Squarepoint, an estimated $26.3K added.
- The largest Moleculin Biotech seller in Q1 2023 was Charles Schwab, an estimated $38.8K sold.
Based on aggregated 13F filings for Q1 2023.